Description: Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.
Home Page: immuneering.com
IMRX Technical Analysis
245 Main Street
Cambridge,
MA
02142
United States
Phone:
617 500 8080
Officers
| Name | Title |
|---|---|
| Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. | Co-Founder, Pres, CEO & Director |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer |
| Ms. Mallory Morales CPA | VP of Fin., Principal Financial & Accounting Officer and Treasurer |
| Ms. Paula George CPA | Sr. Mang. of Accounting & Operations |
| Mr. Michael D. Bookman J.D. | Gen. Counsel & Sec. |
| Ms. Leah R. Neufeld | Chief People Officer |
| Dr. Scott Barrett M.D. | Chief Medical Officer |
| Dr. Mohamedi Kagalwala M.B.A., Ph.D. | Head of Neuroscience Devel. |
| Dr. Peter King Ph.D. | Head of Discovery & VP |
| Dr. Rajaraman Krishnan Ph.D. | Head of Neuroscience Discovery |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1221 |
| Price-to-Sales TTM: | 238.4358 |
| IPO Date: | 2021-07-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 74 |